3.8 Article

Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age

期刊

HUMAN VACCINES
卷 3, 期 1, 页码 14-22

出版社

LANDES BIOSCIENCE
DOI: 10.4161/hv.3.1.3657

关键词

cost-effectiveness; virosomal adjuvanted influenza vaccine; 6 to 60-month-old children

向作者/读者索取更多资源

This study estimated the health and economic outcomes of universal administration of a adjuvanted influenza vaccine to healthy preschool children, as compared with current immunization practice. A Markov model simulated a cohort of 3 million children and their households undergoing five influenza seasons. Assuming a vaccine uptake rate of 30%, at the current acquisition cost of EURO5.50 per vaccine dose influenza vaccination (two doses for unprimed children) of 6- to 60-month- (5-year) old children averted more than 1 million clinical influenza episodes and saved EURO63 million, from the perspective of the Italian society. From the perspective of the Italian health care service, influenza vaccination of 6- to 60- and of 6- to 24-month-old children cost EURO 10,000 and EURO 13,333 per quality-adjusted life year (QALY) saved, respectively. Administration of a adjuvanted influenza vaccine to children aged 6 to 60 months was highly cost-effective for the health care service and cost saving for the society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据